Molecular Reagent NuLexa™ Influenza + SARS CLIA Waived For NuLexa Instrument 50 Tests

Features

• NULEXA Influenza + SARS Test is an automated rapid multiplex real-time, reverse transcriptase polymerase chain reaction (RT-PCR) test performed on the NULEXA Instrument and is intended for the simultaneous qualitative detection and differentiation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A, and influenza B virus nucleic acid in anterior nasal swab (ANS) specimens from individuals with signs and symptoms of respiratory tract infection
• The CLIA waived NULEXA System brings together high speed and high sensitivity in a PCR molecular system that redefines point-of-care diagnostics
• NULEXA Influenza + SARS Test reports positive results in as little as 6 minutes with multiplex detection and differentiation of Flu A, Flu B and COVID-19
• Cleared for use in healthcare facilities operating under a CLIA Certificate of Waiver, the NULEXA System has a fully automated swab-to-result workflow that requires no swab elution, liquid sample handling or result interpretation
• Each kitted box contains: NULEXA Influenza + SARS Test Cartridges (50) packaged individually in foil pouches; each Test Cartridge contains all necessary reagents for sample processing and detection of viral RNA targets, including the SPC, Sterile Anterior Nasal Swabs (52), packaged individually in peel pouches (allowing spares), Quick Ref Guide, Quality Control Procedure